References
- van Venrooij W. J., Zendman A. J., Pruijn G. J. Autoantibodies to citrullinated antigens in (early) rheumatoid arthritis. Autoimmun Rev 2006; 6: 37–41
- Dejaco C., Klotz W., Larcher H., Duftner C., Schirmer M., Herold M. Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res Ther 2006; 8: R119
- Bang H., Egerer K., Gauliard A., Luthke K., Rudolph P. E., Fredenhagen G., et al. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 2007; 56: 2503–11
- Mathsson L., Mullazehi M., Wick M. C., Sjöberg O., van Vollenhoven R., Klareskog L., et al. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum 2007; 58: 36–45
- Bobbio‐Pallavicini F., Caporali R., Alpini C., Moratti R., Montecucco C. Predictive value of antibodies to citrullinated peptides and rheumatoid factors in anti‐TNF‐alpha treated patients. Ann N Y Acad Sci 2007; 1109: 287–95
- van Gestel A. M., Prevoo M. L., van ‘t Hof M. A., van Rijswijk M. H., van de Putte L. B., van Riel P. L. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996; 39: 34–40
- Atzeni F., Turiel M., Capsoni F., Doria A., Meroni P., Sarzi‐Puttini P. Autoimmunity and anti‐TNF‐alpha agents. Ann N Y Acad Sci 2005; 1051: 559–69
- Bobbio‐Pallavicini F., Caporali R., Alpini C., Avalle S., Epis O. M., Klersy C., et al. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis. Ann Rheum Dis 2007; 66: 302–7
- Atzeni F., Sarzi‐Puttini P., Dell' Acqua D., de Portu S., Cecchini G., Cruini C., et al. Adalimumab clinical efficacy is associated with rheumatoid factor and anti‐cyclic citrullinated peptide antibody titre reduction: a one‐year prospective study. Arthritis Res Ther 2005; 8: R3
- Mikuls T. R., O'Dell J. R., Stoner J. A., Parrish L. A., Arend W. P., Norris J. M., et al. Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti‐cyclic citrullinated peptide antibody. Arthritis Rheum 2004; 50: 3776–82